Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib as Post-Transplant Maintenance in Acute Leukemia
NCT06575296Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Dec 2024
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of revumenib in acute leukemia, sponsored by City of Hope. Primary endpoint: Incidence of adverse events up to 2 years. Started Dec 2024; status: recruiting.
02
Drugs
revumenib
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT06575296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06575296.